Active, not recruitingPhase 2NCT04762069
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CNS Pharmaceuticals, Inc.
- Principal Investigator
- Sandra Silberman, MD, PhDCNS Pharmaceuticals, Inc.
- Intervention
- Berubicin(drug)
- Enrollment
- 252 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- University of Arkansas, Little Rock, Arkansas, United States
- Southern California Permanente Medical Group, Los Angeles, California, United States
- University of California Irvine, Orange, California, United States
- University of Califonia San Diego Moores Cancer Center, San Diego, California, United States
- University of California San Francisco, San Francisco, California, United States
- Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States
- HCA Healthcare Research Institute, Englewood, Colorado, United States
- Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Baptist Miami, Miami, Florida, United States
- Piedmont Healthcare, Atlanta, Georgia, United States
- Rush University Cancer Center, Chicago, Illinois, United States
- University of Kentucky, Lexington, Kentucky, United States
- Tulane Cancer Center Clinic, New Orleans, Louisiana, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Worldwide Clinical Trials
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04762069 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland